Profile: Inimex Pharmaceuticals, Inc. is a clinical stage company focused on the development & supply of innate defense regulators, first in class drugs that selectively trigger the body's innate defenses without causing inflammation. We offer products for infectious disease, cancer and inflammatory disease. Our IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant staphylococcus aureus or vancomycin-resistant enterococcus. Our IMX942 is active against both normal & drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. Our first generation IDR products are short peptides suitable for parenteral, aerosol, or topical administration.